The Depo-Provera lawsuit is one of the largest active pharmaceutical mass torts in the United States right now. Thousands of women who used the injectable birth control and later developed brain tumors are pursuing claims against Pfizer in 2026.
This article covers everything you need to know. You’ll learn the current case status, who qualifies, what settlements might look like, and how to get your claim started.
One number puts the scale of this in perspective. By early 2026, more than 6,000 lawsuits had been filed in the consolidated federal litigation. That number keeps climbing.
Read this from top to bottom and you’ll have a clear picture of where the case stands and what your options are.
Depo Provera Lawsuit Update: Where Things Stand Right Now
The Depo-Provera lawsuit is currently in the pretrial discovery and bellwether selection phase inside a federal multidistrict litigation (MDL) court.
As of early 2026, the case is consolidated in the U.S. District Court for the Northern District of Illinois under MDL 3140, presided over by Judge Matthew Kennelly. Plaintiffs and Pfizer’s defense team are exchanging expert witness disclosures and medical records on a court-ordered schedule.
Bellwether trials, which are small test cases that signal how juries react to evidence, are expected to begin in late 2026. These results will shape settlement negotiations dramatically.
No global settlement has been reached yet. But legal analysts watching this MDL say the volume of claims and the strength of the scientific evidence make a settlement resolution highly probable before the MDL reaches full trial scale.
| Status Item | Current Status (2026) |
|---|---|
| MDL Court | Northern District of Illinois |
| MDL Number | MDL 3140 |
| Presiding Judge | Judge Matthew Kennelly |
| Total Cases Filed | 6,000+ as of early 2026 |
| Current Phase | Discovery and bellwether preparation |
| First Bellwether Trials | Expected late 2026 |
| Global Settlement | Not yet reached |
What Is New in the Depo Provera Lawsuit Updates for 2026
The biggest depo provera lawsuit updates for 2026 center on expert discovery, case management orders, and the court’s bellwether trial selection process.
In January 2026, Judge Kennelly issued a Case Management Order setting firm deadlines for both sides to produce general causation expert reports. This is a pivotal step. If the plaintiffs’ scientific experts survive Daubert challenges, Pfizer’s defense options narrow considerably.
The court also formally identified a pool of 24 potential bellwether cases in early 2026. Both Pfizer and plaintiff attorneys will strike cases from this pool until a smaller trial group is finalized.
Pfizer has continued to contest general causation, arguing the scientific link between medroxyprogesterone acetate and meningioma growth is not proven to the legal standard. The plaintiffs’ legal teams counter with multiple peer-reviewed studies, including the high-profile 2024 French national cohort study published in a leading medical journal.
- January 2026: Expert disclosure deadlines set by court order
- Early 2026: 24-case bellwether pool formally identified
- Ongoing: General causation Daubert briefing
- Mid-2026: Expected Daubert hearing on expert testimony admissibility
- Late 2026: First bellwether trials projected to begin
Key point for claimants: 2026 is an active and consequential year in this litigation. Being registered and represented before bellwether outcomes are announced puts you in the strongest position.
The Depo Provera Brain Tumor Lawsuit Explained
The Depo-Provera brain tumor lawsuit claims that long-term use of the injectable contraceptive caused women to develop a specific type of brain tumor called an intracranial meningioma.
Medroxyprogesterone acetate, the active ingredient in Depo-Provera, is a synthetic progestogen hormone. Meningiomas are tumors that grow on the membranes surrounding the brain and spinal cord. Research shows that progesterone receptors are present on meningioma cells, which is the biological mechanism at the center of these lawsuits.
A 2024 cohort study involving hundreds of thousands of French women found that long-term Depo-Provera users had a dramatically elevated meningioma risk compared to non-users. This study directly accelerated the filing surge in U.S. courts.
The lawsuit does not claim that every woman who used the shot will develop a tumor. It claims Pfizer knew or should have known about the elevated risk and failed to warn patients and doctors adequately.
Think of it like the early asbestos cases. The harm was real. The cover-up of risk was the core legal problem.
| Tumor Type | Relevance to Lawsuit |
|---|---|
| Intracranial Meningioma (Grade 1) | Primary compensable diagnosis |
| Intracranial Meningioma (Grade 2) | Higher compensation tier likely |
| Intracranial Meningioma (Grade 3) | Highest severity, highest damages |
| Other brain tumors | Evaluated case by case |
Key Takeaway: The Depo-Provera lawsuit is in active litigation inside MDL 3140 in Illinois, with bellwether trials expected in late 2026, and the scientific evidence driving the case centers on a confirmed link between medroxyprogesterone acetate and meningioma growth.
Understanding the Depo Provera Meningioma Lawsuit
The Depo-Provera meningioma lawsuit specifically targets the connection between prolonged exposure to medroxyprogesterone acetate and the growth of meningiomas in the brain.
Not all meningiomas behave the same way. Grade 1 tumors are typically slow-growing and often benign, though they can cause significant neurological symptoms as they press against brain tissue. Grade 2 and Grade 3 meningiomas are more aggressive and often require surgery, radiation, or both.
The severity of the diagnosed meningioma matters enormously in these lawsuits. A woman who required brain surgery to remove a Grade 2 meningioma will likely receive a higher settlement value than a woman whose Grade 1 tumor was small and monitored without treatment.
This grading distinction is something no competitor article fully explains. It is one of the most important factors attorneys use when evaluating the strength and value of a claim.
- Grade 1 Meningioma: Slow-growing, often manageable with monitoring
- Grade 2 (Atypical) Meningioma: Moderate aggression, higher recurrence risk
- Grade 3 (Anaplastic) Meningioma: Aggressive, requires active treatment, strongest case value
Plaintiffs must provide imaging records, pathology reports, and treatment history. These documents are the backbone of any meningioma claim.
Who Qualifies for the Depo Provera Lawsuit
Women who used Depo-Provera for an extended period and were later diagnosed with an intracranial meningioma are the primary group who qualify for this lawsuit.
There are several factors attorneys look at when screening potential claimants. The length of use is one of the most important. Most law firms currently focusing on this litigation look for women who used Depo-Provera for at least one year, with stronger cases built around two or more years of continuous use.
The diagnosis must be documented. An imaging study (MRI or CT scan) confirming the presence of an intracranial meningioma is required. Self-reported symptoms alone are not enough.
| Qualification Factor | General Requirement |
|---|---|
| Product used | Depo-Provera (medroxyprogesterone acetate injection) |
| Minimum use period | 1+ years (2+ years preferred) |
| Diagnosis required | Intracranial meningioma (documented) |
| Medical records | MRI or CT imaging confirming diagnosis |
| Treatment received | Surgery, radiation, or active monitoring |
Family members of women who died from meningioma-related complications may also be eligible to file on behalf of the deceased.
Depo Provera Lawsuit Eligibility Requirements in Detail
The depo provera lawsuit eligibility requirements go beyond simply having used the drug. Courts and law firms apply specific criteria to determine if a claim is viable.
First, the injection must have been the brand-name Depo-Provera product or its generic equivalent containing medroxyprogesterone acetate. Oral progestin-only contraceptives are not part of this litigation.
Second, the meningioma diagnosis must have occurred after a documented period of Depo-Provera use. Cases where the tumor was pre-existing before Depo-Provera use began face significant legal challenges and may not qualify.
Third, the statute of limitations must not have expired. This varies by state, which is covered in a dedicated section below.
- Used injectable medroxyprogesterone acetate (Depo-Provera brand or generic)
- Used the drug for at least 12 consecutive months
- Diagnosed with an intracranial meningioma after beginning use
- Diagnosis confirmed by imaging or pathology report
- Claim filed within the applicable statute of limitations window
Medical records and prescription history are the key documents attorneys will request first. If you no longer have your prescription records, pharmacy records and medical chart notes from your OB-GYN or family doctor can substitute.
Depo Provera Lawsuit Payout Amounts: What Are Cases Worth
Depo-Provera lawsuit payout amounts are not officially set yet because no global settlement agreement has been reached as of 2026.
That said, legal analysts watching similar pharmaceutical mass torts give a reasonable framework. Cases involving brain surgery, significant cognitive impairment, or life-altering neurological damage tend to settle in the range of $300,000 to over $1 million per plaintiff in comparable mass torts.
Cases with documented diagnosis but minimal treatment and limited functional impact typically settle in lower ranges, often between $50,000 and $200,000 in similar litigation.
These are projections based on comparable cases, not guaranteed amounts.
| Injury Severity | Estimated Value Range (Comparable Mass Torts) |
|---|---|
| Grade 1 meningioma, monitored only | $50,000 to $150,000 |
| Grade 1 requiring surgery | $100,000 to $300,000 |
| Grade 2 meningioma with treatment | $200,000 to $600,000 |
| Grade 3 meningioma, severe outcomes | $500,000 to $1,000,000+ |
| Wrongful death cases | Varies widely, often highest tier |
Attorney fees in mass tort cases are typically contingency-based, meaning the lawyer takes a percentage of the recovery. Most mass tort firms charge 33% to 40% of the final settlement.
Key Takeaway: Eligibility hinges on documented meningioma diagnosis after at least one year of Depo-Provera use, and payout estimates in comparable mass torts range from $50,000 to over $1 million depending on injury severity, though no official settlement figures exist yet for this litigation.
Depo Provera Settlement 2026: What to Expect
A Depo-Provera settlement in 2026 has not been officially announced, but the structure of the litigation makes a negotiated resolution increasingly likely by late 2026 or 2027.
Pharmaceutical mass torts almost always settle. Companies like Pfizer rarely take thousands of individual cases to trial. The bellwether trial results expected in late 2026 will be the most significant pressure point for bringing both sides to the negotiating table.
If plaintiffs win the first bellwether trials decisively, Pfizer’s incentive to settle quickly and on favorable terms to plaintiffs increases substantially. If results are mixed, negotiations may extend into 2027.
Settlement funds in pharmaceutical mass torts are typically structured as tiered compensation grids. Plaintiffs are placed into tiers based on injury severity, duration of use, and treatment received. Each tier has a defined payout range.
- Bellwether outcomes: Expected late 2026
- Settlement negotiations: Likely to intensify after first trial results
- Global settlement announcement: Potentially 2026 to 2027
- Individual payment distribution: Typically 12 to 24 months after settlement agreement
The important thing to understand is that you do not need to wait for the settlement to register your claim. Getting your case on file now protects your place in line.
Is There a Depo Provera Class Action Settlement
The Depo-Provera litigation is structured as a mass tort, not a traditional class action settlement, and this distinction matters for how you get paid.
In a class action, all plaintiffs share one pool of money and receive the same or similarly calculated payouts. In a mass tort like this one, each plaintiff’s case is evaluated individually. Your payout is based on your specific injury, medical history, and damages.
This structure generally benefits plaintiffs with more serious injuries. A woman who had brain surgery receives far more than someone whose tumor was discovered incidentally and required no treatment.
There is no class action settlement to “join” in the traditional sense. Each claim must be filed individually, screened by an attorney, and formally docketed in the MDL.
| Lawsuit Type | Payment Structure | Who Benefits Most |
|---|---|---|
| Class Action | Shared fund, equal or formula-based | Large groups with minor individual harm |
| Mass Tort (Depo-Provera) | Individual case evaluation | Those with serious injuries |
Some law firms may market this as a “class action” loosely. The technical and practical reality is that it functions as a mass tort with individual case values.
Pfizer and the Depo Provera Lawsuit: Their Role Explained
Pfizer is the primary defendant in the Depo-Provera lawsuit because the company has manufactured and marketed the drug in the United States for decades.
Depo-Provera was approved by the FDA in 1992 for use as a contraceptive injection. Pfizer acquired the drug through its corporate history and has been responsible for its labeling and marketing since then. The lawsuit alleges Pfizer failed to adequately warn women and their healthcare providers that long-term use was associated with elevated meningioma risk.
Pfizer has not publicly admitted any wrongdoing. The company’s legal strategy has focused on challenging the general causation science, arguing the epidemiological evidence does not meet the legal threshold to establish that the drug causes meningiomas in a legally actionable way.
This is a standard defense strategy in pharmaceutical litigation. It mirrors how defendants in talc, Roundup, and similar cases initially challenged causation before eventually settling.
- Pfizer’s defense: Causation not legally established
- Plaintiffs’ argument: Scientific evidence meets standard, labeling was inadequate
- FDA action: The FDA has not issued a formal warning specifically about meningiomas as of early 2026, though labeling discussions are ongoing
- Pfizer’s financial exposure: Analysts estimate potential total liability in the billions if the case proceeds to large-scale settlements
Key Takeaway: The Depo-Provera mass tort is structured as individual-claim litigation rather than a traditional class action, Pfizer is the primary defendant contesting causation, and a global settlement is expected to be driven by bellwether trial results in late 2026.
Depo Provera MDL Update 2026: Court Progress
The Depo-Provera MDL update for 2026 reflects a case that has moved from early organizational stages into substantive legal combat over the science and individual case facts.
MDL 3140 was formally established in late 2024. Throughout 2025, the court focused on establishing administrative orders, setting up plaintiff fact sheets, and building the general framework for managing thousands of individual claims in one coordinated forum.
By early 2026, the litigation entered a more aggressive phase. Both sides filed expert reports on general causation. These reports detail what each side’s scientific experts say about whether medroxyprogesterone acetate can and does cause meningioma growth.
The upcoming Daubert hearing is critical. A Daubert hearing is where the judge determines whether each side’s expert scientific witnesses are qualified to testify. If the judge excludes the plaintiffs’ causation experts, the entire litigation could collapse. If Pfizer’s experts are excluded or weakened, the company’s defense weakens dramatically.
| MDL Milestone | Date |
|---|---|
| MDL Established | Late 2024 |
| Administrative orders set | Early 2025 |
| Plaintiff Fact Sheets filed | Mid 2025 |
| General causation expert reports | Early 2026 |
| Daubert hearing (projected) | Mid 2026 |
| Bellwether trial pool finalized | Mid 2026 |
| First bellwether trials | Late 2026 |
Depo Provera Lawsuit Trial Dates 2026
The first Depo-Provera lawsuit trial dates in 2026 are expected in the fall of 2026, pending the outcome of Daubert hearings on expert testimony.
These initial trials will not decide every plaintiff’s case. They are bellwether cases, meaning they are representative trials selected to test how real juries respond to the evidence and arguments on both sides.
If a jury awards significant damages to the first plaintiff, the legal community watches that verdict as a gauge of what thousands of similar claims might be worth in settlement. It is the same mechanism that drove mass settlements in cases involving Roundup, Pradaxa, and talcum powder.
The schedule is subject to court management. Judges in complex MDL cases routinely adjust trial calendars. However, Judge Kennelly has maintained firm deadline pressure in case management orders issued so far.
- Mid-2026: Daubert hearing on general causation expert testimony
- Mid to Late 2026: Bellwether trial pool finalized from 24-case pool
- Fall 2026: First bellwether trial(s) expected to begin
- Late 2026 to Early 2027: Verdict(s) expected
- 2027: Settlement negotiations expected to intensify based on verdicts
The fall 2026 timeline is the most important date in this entire litigation right now.
Depo Provera Lawsuit Symptoms That Support a Claim
The Depo-Provera lawsuit symptoms that matter most are those directly linked to an intracranial meningioma diagnosis, not general side effects from the injection itself.
This distinction confuses many potential claimants. Experiencing irregular periods, bone density loss, or injection-site discomfort from Depo-Provera does not alone qualify someone for this lawsuit. The compensable harm is the brain tumor.
Meningioma symptoms that may have preceded a formal diagnosis include persistent and worsening headaches, vision changes or double vision, hearing changes or ringing, memory problems, seizures, weakness on one side of the body, and difficulty with speech or balance.
Many women had these symptoms for months or years before getting an MRI that revealed the tumor. The timeline between symptom onset, diagnosis, and Depo-Provera use is something your attorney will document carefully.
| Symptom | Why It Matters |
|---|---|
| Persistent headaches | Common early meningioma symptom |
| Vision changes | Tumor pressing on optic nerve |
| Cognitive changes | Tumor affecting frontal or parietal lobe |
| Hearing problems | Tumor location near auditory pathways |
| Seizures | Tumor irritating brain tissue |
| Balance or coordination issues | Tumor near cerebellum or brainstem |
If you experienced any of these and later received an MRI confirming a meningioma, that diagnostic chain is exactly what attorneys need to build your claim.
Depo Provera Long Term Side Effects and the Lawsuit
The Depo-Provera long term side effects at the center of the lawsuit go well beyond what the product label warned about for most of its history on the market.
Pfizer’s label warned of side effects like irregular bleeding, weight changes, and bone density loss. It did not prominently warn that years of use could be associated with meningioma growth. This alleged failure to warn is a core theory in the product liability claims.
Research published in scientific journals, including a major French cohort study in 2024, found that women who used Depo-Provera for more than a year had a risk of meningioma significantly above the general population. The longer the use, the more pronounced the association appeared in the data.
For legal purposes, the relevant long term side effect is specifically the development of an intracranial meningioma requiring medical intervention. Claims based on other long term effects, such as bone density concerns alone, are not currently part of this MDL.
- Bone density loss: Known, labeled, not part of this lawsuit
- Irregular bleeding: Known, labeled, not part of this lawsuit
- Intracranial meningioma: Alleged failure to warn, core of this lawsuit
- Cognitive decline from tumor: Compensable as downstream harm
Key Takeaway: The Depo-Provera MDL is on pace for its first bellwether trials in fall 2026, the qualifying injury is specifically an intracranial meningioma rather than general side effects, and the failure-to-warn theory is the primary legal argument driving the litigation.
Depo Provera Lawsuit Statute of Limitations: Your Deadline
The Depo-Provera lawsuit statute of limitations is one of the most time-sensitive issues in this entire case, and missing it can permanently bar your claim.
Every state sets its own deadline for filing personal injury lawsuits. Most states allow two to three years from the date you discovered (or reasonably should have discovered) your injury. In this context, that typically means two to three years from when you were diagnosed with a meningioma.
Some states use the “discovery rule,” which means the clock starts when you connect the injury to the drug, not necessarily the day of diagnosis. If you were diagnosed with a meningioma years ago but only recently learned about the Depo-Provera connection, you may still have time to file.
| State | General Statute of Limitations | Notes |
|---|---|---|
| California | 2 years | Discovery rule applies |
| Texas | 2 years | From date of injury or discovery |
| New York | 3 years | From discovery in some drug cases |
| Florida | 2 years | Product liability standard |
| Illinois | 2 years | Personal injury standard |
This table provides general guidance only. Your specific deadline depends on when your diagnosis occurred, your state of residence, and other case-specific factors. Get your claim reviewed now rather than assuming you have time.
How to File a Depo Provera Claim in 2026
Filing a Depo-Provera claim in 2026 is a straightforward process when you work with a law firm that is already handling cases inside MDL 3140.
The first step is an initial consultation. Most mass tort attorneys offer free case reviews. You will describe your Depo-Provera use history and your meningioma diagnosis. The attorney’s intake team will assess whether your claim meets the basic criteria.
If your case is accepted, the attorney will gather your medical records, prescription history, and imaging studies. They file a complaint on your behalf, which gets docketed into the MDL. You do not go to a local courthouse or attend any hearings at this stage.
- Step 1: Contact a mass tort attorney for a free case review
- Step 2: Provide medical records and prescription history
- Step 3: Attorney files individual complaint in MDL 3140
- Step 4: Your case is docketed and you complete a Plaintiff Fact Sheet
- Step 5: Discovery proceeds as part of the coordinated MDL process
- Step 6: Your case is evaluated for bellwether selection or settlement placement
The entire early process is handled primarily by your legal team. Your main job is to gather your medical records and stay in contact with your attorney.
Depo Provera Lawsuit Compensation: Types of Damages Available
Depo-Provera lawsuit compensation covers several categories of damages, and understanding each type helps you see why cases with severe injuries command significantly higher settlements.
Economic damages are the straightforward financial losses. These include past and future medical expenses, surgical costs, radiation treatment costs, lost wages if the tumor or its treatment forced you out of work, and future lost earning capacity.
Non-economic damages cover the harder-to-quantify but equally real harms. Pain and suffering, loss of enjoyment of life, emotional distress, and the loss of normal cognitive function all fall here. These damages are often the largest component of a payout in meningioma cases because brain surgery and tumor growth can permanently alter a person’s life.
Punitive damages are a third category. These are awarded when a jury finds that the defendant acted with reckless disregard for public safety. If evidence shows Pfizer had internal knowledge of the meningioma risk and suppressed it, punitive damages become a real possibility at trial.
| Damage Type | What It Covers | Example |
|---|---|---|
| Economic | Medical bills, lost wages | $200,000 brain surgery + 3 months missed work |
| Non-Economic | Pain, suffering, cognitive loss | Life permanently changed by neurological effects |
| Punitive | Defendant’s misconduct | Internal documents showing suppressed risk data |
Compensation from all three categories is combined into a single settlement figure for each plaintiff.
Depo Provera Lawsuit News: Key Developments to Follow
The most important depo provera lawsuit news to track in 2026 centers on three events: the Daubert ruling, the bellwether trial schedule, and any movement toward global settlement talks.
The Daubert hearing, expected in mid-2026, will determine whether the plaintiffs’ scientific experts can testify at trial. This ruling is the biggest single event of the year in this litigation. A ruling in the plaintiffs’ favor will accelerate the case toward trial and settlement. An adverse ruling could force appellate proceedings and delay resolution.
Following the Daubert outcome, watch for the court’s finalized bellwether trial schedule. The judge will narrow the 24-case pool to a smaller group for actual trial. The selection process reveals which types of cases each side considers strongest.
Global settlement news is less predictable on a fixed timeline. Pharmaceutical companies typically open serious settlement discussions only after they see how one or two bellwether verdicts land with a jury. Think of bellwether verdicts as the opening bid in a negotiation that involves thousands of individual claims.
- Mid-2026: Daubert ruling on general causation experts (watch closely)
- Mid to Late 2026: Bellwether trial group finalized
- Fall 2026: First trial begins
- Late 2026 to 2027: Settlement pressure builds based on verdict outcomes
- Ongoing: FDA label review discussions; any new published research
Sign up for updates through your attorney. If you are not yet represented, following reliable legal news sources that cover MDL developments will keep you informed.
Key Takeaway: The three events to watch in 2026 are the Daubert hearing, the first bellwether trial, and any global settlement announcement, because each one directly affects how much individual claimants can expect to receive and when.
Frequently Asked Questions
What is the current status of the Depo-Provera lawsuit in 2026?
The Depo-Provera lawsuit is in active litigation inside MDL 3140 in the U.S. District Court for the Northern District of Illinois.
The case is currently in the expert discovery and bellwether preparation phase as of early 2026.
First bellwether trials are expected to begin in fall 2026, with a Daubert hearing on expert testimony projected for mid-2026.
How much compensation can I get from the Depo-Provera lawsuit?
No official settlement amounts have been set yet because no global settlement agreement exists as of 2026.
Based on comparable pharmaceutical mass torts, estimates range from $50,000 for minor cases to over $1 million for cases involving brain surgery and severe neurological harm.
The final amount depends on your meningioma grade, treatment received, medical costs, and lost income.
Who qualifies to file a Depo-Provera brain tumor lawsuit?
Women who used Depo-Provera for at least one year and were later diagnosed with an intracranial meningioma generally qualify.
The diagnosis must be confirmed by MRI or CT imaging, and medical records must document both the drug use and the tumor diagnosis.
Family members of women who died from meningioma complications related to Depo-Provera use may also be eligible to file.
What is the deadline to file a Depo-Provera claim?
The deadline depends on your state’s statute of limitations, which typically runs two to three years from the date of your meningioma diagnosis.
Some states apply the discovery rule, meaning the clock starts when you connected your diagnosis to Depo-Provera use rather than the diagnosis date itself.
Getting legal advice as soon as possible is the safest approach because deadlines vary and missing yours permanently bars your claim.
Is the Depo-Provera lawsuit a class action or a mass tort?
The Depo-Provera litigation is structured as a mass tort, not a traditional class action.
Each plaintiff’s case is evaluated individually, and payouts are based on personal injury severity rather than a shared settlement pool.
This structure generally means higher individual payouts for those with serious injuries compared to a class action distribution model.
Where Things Go From Here
The fall 2026 bellwether trials are the turning point that will define this entire litigation. Every woman with a pending claim has a direct stake in those outcomes.
If you used Depo-Provera and have been diagnosed with a meningioma, the time to act is now. Statute of limitations deadlines are real, and getting your case properly filed before a global settlement is announced protects your position.
Gather your medical records, confirm your Depo-Provera prescription history, and speak with a mass tort attorney experienced in this MDL. The process is free to start and costs nothing unless you recover.
